BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 25457209)

  • 1. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
    Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
    J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.
    Xu M; Li Y; Zhang S; Wang X; Shen J; Zhang S
    Ann Hepatol; 2019; 18(3):456-460. PubMed ID: 31054977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
    Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
    J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
    Krawczyk M; Jiménez-Agüero R; Alustiza JM; Emparanza JI; Perugorria MJ; Bujanda L; Lammert F; Banales JM
    Surg Obes Relat Dis; 2016 Dec; 12(10):1838-1846. PubMed ID: 27576208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity.
    Hyysalo J; Gopalacharyulu P; Bian H; Hyötyläinen T; Leivonen M; Jaser N; Juuti A; Honka MJ; Nuutila P; Olkkonen VM; Oresic M; Yki-Järvinen H
    Diabetes; 2014 Jan; 63(1):312-22. PubMed ID: 24009255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
    Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
    Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.
    Coppola N; Rosa Z; Cirillo G; Stanzione M; Macera M; Boemio A; Grandone A; Pisaturo M; Marrone A; Adinolfi LE; Sagnelli E; Miraglia del Giudice E
    Liver Int; 2015 Aug; 35(8):1959-63. PubMed ID: 25581573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP).
    Arslanow A; Stokes CS; Weber SN; Grünhage F; Lammert F; Krawczyk M
    Liver Int; 2016 Mar; 36(3):418-26. PubMed ID: 26264356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.
    Luukkonen PK; Zhou Y; Nidhina Haridas PA; Dwivedi OP; Hyötyläinen T; Ali A; Juuti A; Leivonen M; Tukiainen T; Ahonen L; Scott E; Palmer JM; Arola J; Orho-Melander M; Vikman P; Anstee QM; Olkkonen VM; Orešič M; Groop L; Yki-Järvinen H
    J Hepatol; 2017 Jul; 67(1):128-136. PubMed ID: 28235613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
    Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
    Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
    Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
    Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children.
    Grandone A; Cozzolino D; Marzuillo P; Cirillo G; Di Sessa A; Ruggiero L; Di Palma MR; Perrone L; Miraglia Del Giudice E
    Pediatr Obes; 2016 Apr; 11(2):115-9. PubMed ID: 25893821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.
    Park JH; Cho B; Kwon H; Prilutsky D; Yun JM; Choi HC; Hwang KB; Lee IH; Kim JI; Kong SW
    Liver Int; 2015 Dec; 35(12):2537-46. PubMed ID: 26148225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
    Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
    J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
    Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
    Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.
    Dongiovanni P; Petta S; Maglio C; Fracanzani AL; Pipitone R; Mozzi E; Motta BM; Kaminska D; Rametta R; Grimaudo S; Pelusi S; Montalcini T; Alisi A; Maggioni M; Kärjä V; Borén J; Käkelä P; Di Marco V; Xing C; Nobili V; Dallapiccola B; Craxi A; Pihlajamäki J; Fargion S; Sjöström L; Carlsson LM; Romeo S; Valenti L
    Hepatology; 2015 Feb; 61(2):506-14. PubMed ID: 25251399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.
    Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.
    Borén J; Adiels M; Björnson E; Matikainen N; Söderlund S; Rämö J; Ståhlman M; Ripatti P; Ripatti S; Palotie A; Mancina RM; Hakkarainen A; Romeo S; Packard CJ; Taskinen MR
    JCI Insight; 2020 Dec; 5(24):. PubMed ID: 33170809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Patatin-Like Phospholipase Domain-Containing 3 Gene for Hepatic Lipid Content and Insulin Resistance in Diabetes.
    Zaharia OP; Strassburger K; Knebel B; Kupriyanova Y; Karusheva Y; Wolkersdorfer M; Bódis K; Markgraf DF; Burkart V; Hwang JH; Kotzka J; Al-Hasani H; Szendroedi J; Roden M;
    Diabetes Care; 2020 Sep; 43(9):2161-2168. PubMed ID: 32910776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining I148M and E167K variants to improve risk prediction for nonalcoholic fatty liver disease in Qingdao Han population, China.
    Chen LZ; Ding HY; Liu SS; Liu Q; Jiang XJ; Xin YN; Xuan SY
    Lipids Health Dis; 2019 Feb; 18(1):45. PubMed ID: 30738435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.